
    
      In this study, the effect of patient education on reported bone pain in breast cancer
      patients receiving adjuvant or neoadjuvant chemotherapy and pegfilgrastim will be
      investigated.

      Each patient will receive adjuvant or neoadjuvant chemotherapy with pegfilgrastim
      prophylaxis, beginning in the first cycle and continuing throughout the study period. The
      study period for this study is the first 4 cycles of chemotherapy. participants can be
      planning to receive regimens with > 4 cycles, but data will only be collected for the first 4
      cycles. The choice of chemotherapy regimen (agent, dose, and schedule) is at the discretion
      of the treating physician. Commercially available pegfilgrastim will be administered
      according to US Prescribing Information and is considered background therapy.
    
  